Dihydropyridine Calcium Channel Antagonists Reduce Immobility in the Mouse Behavioral Despair Test; Antidepressants Facilitate Nifedipine Action

Overview

Journal Eur J Pharmacol

Specialty Pharmacology

Date 1987 Jun 26

PMID 3622617

Citations 26

Authors

E Mogilnicka

A Czyrak

J Maj

Affiliations

Soon will be listed here.

Abstract

The effect of the calcium channel antagonists nifedipine, nitrendipine, nimodipine, verapamil and diltiazem in the mouse behavioral despair test was investigated. The dihydropyridine calcium channel antagonists nifedipine, nitrendipine, nimodipine (0.1, 1, 10 mg/kg p.o.) but not the non-dihydropyridine compounds verapamil or diltiazem, dose dependently reduced immobility. Various antidepressant drugs (imipramine, mianserin, citalopram, (+)oxaprotiline) and (-)oxaprotiline in combination with nifedipine facilitated its effect.

Citing Articles

L-type calcium channel regulation of depression, anxiety and anhedonia-related behavioral phenotypes following chronic stress exposure.

Nunes E, Kebede N, Rajadhyaksha A, Addy N Neuropharmacology. 2024; 257:110031.

PMID: 38871116 PMC: 11334593. DOI: 10.1016/j.neuropharm.2024.110031.

α-Adrenergic receptor-PKC-Pyk2-Src signaling boosts L-type Ca channel Ca1.2 activity and long-term potentiation in rodents.

Man K, Bartels P, Henderson P, Kim K, Shi M, Zhang M Elife. 2023; 12.

PMID: 37338965 PMC: 10325713. DOI: 10.7554/eLife.79648.

Ca1.2 Activity and Downstream Signaling Pathways in the Hippocampus of An Animal Model of Depression.

Moreno C, Hermosilla T, Hardy P, Aballai V, Rojas P, Varela D Cells. 2020; 9(12).

PMID: 33291797 PMC: 7762021. DOI: 10.3390/cells9122609.

Disruption of Cav1.2-mediated signaling is a pathway for ketamine-induced pathology.

Chen H, Vandorpe D, Xie X, Alper S, Zeidel M, Yu W Nat Commun. 2020; 11(1):4328.

PMID: 32859919 PMC: 7455701. DOI: 10.1038/s41467-020-18167-4.

Alterations of Calcium Channels in a Mouse Model of Huntington's Disease and Neuroprotection by Blockage of Ca1 Channels.

Miranda A, Cardozo P, Silva F, de Souza J, Olmo I, Cruz J ASN Neuro. 2019; 11:1759091419856811.

PMID: 31216184 PMC: 6585245. DOI: 10.1177/1759091419856811.